Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketmoversinsider.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketMoversInsider.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent MLTX Stock Price: $57.82
Summary: MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
Thomas Smith analyst at SVB Securities reiterates coverage on MoonLake Immunotherapeutics (MLTX) stock in the energy sector with a Buy rating and has set MLTX's stock price target at $70.
TipRanks.com reports that MoonLake Immunotherapeutics currently has 5 analysts offering 12-month price targets on MLTX and the consensus is a Strong Buy rating with an average stock price target of $68.60. The most recent MLTX stock price we have is $57.82 and we are not making any MLTX forecasts at this time.
In addition, TradingView issued a Strong buy rating for MLTX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on MLTX. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MLTX, please click here >>
Arbutus Biopharma, ABUS
Recent ABUS Stock Price: $2.03
Summary: Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
Ed Arce analyst at H.C. Wainwright reiterates coverage on Arbutus Biopharma (ABUS) stock in the energy sector with a Buy rating and has set ABUS's stock price target at $6.
TipRanks.com reports that Arbutus Biopharma currently has 4 analysts offering 12-month price targets on ABUS and the consensus is a Strong Buy rating with an average stock price target of $4.50. The most recent ABUS stock price we have is $2.03 and we are not making any ABUS forecasts at this time.
In addition, TradingView issued a Strong sell rating for ABUS over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ABUS. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ABUS, please click here >>
Gildan Activewear, GIL
Recent GIL Stock Price: $28.70
Summary: Gildan Activewear Inc. is a manufacturer and marketer of premium quality branded basic activewear for sale principally into the wholesale imprinted activewear segment of the North American apparel market. The company sells premium quality 100% cotton T-shirts and premium quality sweatshirts, in a variety of weights, sizes, colors and styles, as blanks, which are ultimately decorated with designs and logos for sale to consumers.
Martin Landry analyst at Stifel Nicolaus reiterates coverage on Gildan Activewear (GIL) stock in the energy sector with a Buy rating and has set GIL's stock price target at $37.
TipRanks.com reports that Gildan Activewear currently has 5 analysts offering 12-month price targets on GIL and the consensus is a Strong Buy rating with an average stock price target of $37.17. The most recent GIL stock price we have is $28.70 and we are not making any GIL forecasts at this time.
In addition, TradingView issued a sell rating for GIL over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on GIL. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on GIL, please click here >>
Boston Scientific, BSX
Recent BSX Stock Price: $53.42
Summary: Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
Kristen Stewart analyst at C.L. King reiterates coverage on Boston Scientific (BSX) stock in the energy sector with a Buy rating and has set BSX's stock price target at $64.
TipRanks.com reports that Boston Scientific currently has 5 analysts offering 12-month price targets on BSX and the consensus is a Strong Buy rating with an average stock price target of $61.20. The most recent BSX stock price we have is $53.42 and we are not making any BSX forecasts at this time.
In addition, TradingView issued a buy rating for BSX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BSX. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BSX, please click here >>
Sanofi, SNYNF
Recent SNYNF Stock Price: $109.44
Summary: Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
Graham Parry analyst at Bank of America Securities reiterates coverage on Sanofi (SNYNF) stock in the energy sector with a Buy rating and has set SNYNF's stock price target at $143.93.
TipRanks.com reports that Sanofi currently has 5 analysts offering 12-month price targets on SNYNF and the consensus is a Moderate Buy rating with an average stock price target of $117.51. The most recent SNYNF stock price we have is $109.44 and we are not making any SNYNF forecasts at this time.
In addition, TradingView issued a Strong buy rating for SNYNF over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SNYNF. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SNYNF, please click here >>
Roche Holding AG, RHHVF
Recent RHHVF Stock Price: $286.52
Summary: Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
Richard Vosser analyst at J.P. Morgan reiterates coverage on Roche Holding AG (RHHVF) stock in the energy sector with a Sell rating and has set RHHVF's stock price target at $291.58.
TipRanks.com reports that Roche Holding AG currently has 5 analysts offering 12-month price targets on RHHVF and the consensus is a Hold rating with an average stock price target of $305.04. The most recent RHHVF stock price we have is $286.52 and we are not making any RHHVF forecasts at this time.
In addition, TradingView issued a sell rating for RHHVF over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RHHVF. marketmoversinsider.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RHHVF, please click here >>
The editors at marketmoversinsider.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketMoversInsider.com is for serious traders.
==============================================================================
